FILO-COVIM - Observational study on the impact of the COVID-19 epidemic on patients with myeloproliferative neoplasms
Head :
KILADJIAN Jean-Jacques, CIC 1427
Last update : 04/20/2021 | Version : 1 | ID : 73637
| General | |
| Identification | |
| Detailed name | Observational study on the impact of the COVID-19 epidemic on patients with myeloproliferative neoplasms |
| Sign or acronym | FILO-COVIM |
| General Aspects | |
| Medical area |
Hematology |
| Study in connection with Covid-19 |
Yes |
| Health determinants |
Genetic Healthcare system and access to health care services Medicine |
| Scientific investigator(s) (Contact) | |
| Name of the director | KILADJIAN |
| Surname | Jean-Jacques |
| Address | Centre d'Investigations Cliniques - Hôpital Saint-Louis - 75010 Paris |
| secretariat@filo-leucemie.org | |
| Unit | CIC 1427 |
| Organization | Paris Public Hospitals (AP-HP); Inserm |
| Collaborations | |
| Participation in projects, networks and consortia |
Yes |
| Funding | |
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | FILO "French Innovative Leukemia Organization" |
| Organisation status |
Public |
| Presence of scientific or steering committees |
Yes |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database |
Study databases |
| Study databases (details) |
Cohort study |
| Database recruitment is carried out by an intermediary |
A selection of health institutions and services |
| Database recruitment is carried out as part of an interventional study |
No |
| Database objective | |
| Main objective | Describe the rate of serious Coronavirus infections in the different subgroups of patients with myeloproliferative neoplasms defined by ongoing treatment during the epidemic. |
| Inclusion criteria |
Male or female aged 18 years and over
Male or female patient with PV, ET, PMF or MF secondary to PV or ET diagnosed before the COVID-19 pandemic Attending an appointment from April 2020 |
| Population type | |
| Age |
Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
| Population covered |
Sick population |
| Pathology | D45 - Polycythaemia vera |
| III - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | |
| D47 - Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue | |
| Gender |
Male Woman |
| Geography area |
National |
| Data collection | |
| Dates | |
| Date of first collection (YYYY or MM/YYYY) | 2020 |
| Date of last collection (YYYY or MM/YYYY) | 2021 |
| Size of the database | |
| Size of the database (number of individuals) |
[1000-10 000[ individuals |
| Details of the number of individuals | 2000 |
| Data | |
| Database activity |
Current data collection |
| Type of data collected |
Clinical data Declarative data Paraclinical data Biological data |
| Clinical data (detail) |
Direct physical measures |
| Declarative data (detail) |
Face to face interview Phone interview |
| Presence of a biobank |
No |
| Procedures | |
| Followed pathology | |
| Promotion and access | |
| Promotion | |
| Access |
